Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma

Sex: All

Ages: 0 Years – 18 Years

Healthy volunteers: No

Phase: EARLY_PHASE1

Enrollment: 60

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Summary

Medulloblastoma (MB), a rare yet critical pediatric brain tumor, is divided into 4 molecular subgroups (WNT, SHH, Group 3, Group 4), each with distinct genetic profiles. Despite diagnostic and therapeutic advances, neurotoxicity from standard treatments (resection, radiotherapy, chemotherapy) and the need for long-term care remain challenges. CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib), approved for breast cancer, show potential in other tumors, but their efficacy in MB is unclear. Treatment resistance is a concern. This project aims to identify genetic markers of sensitivity to CDK4/6 inhibitors in MB, to improve therapies and overcome resistance.

Eligibility Criteria

Inclusion Criteria: * All patients affected by Medulloblastoma operated on at the Pediatric Neurosurgery Unit during their pediatric age will be elected to take part to the study

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06959979). StuddyBuddy aggregates publicly available trial information.